Back to Search
LYDIA STEELMAN, M.D.
M.D.
Family Medicine Physician
NPI: 1679707475Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
29474(OK)
Research & Publications (20)
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.
PMID 18800146·Leukemia·2009
6-review
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PMID 19305151·Cell Cycle·2009
6-review
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
PMID 18516761·Curr Opin Investig Drugs·2008
7-preclinical
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
PMID 18337766·Leukemia·2008
6-review
Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells.
PMID 18256541·Cell Cycle·2008
8-other
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
PMID 18337767·Leukemia·2008
6-review
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
PMID 18685611·Leukemia·2008
7-preclinical
Targeting prostate cancer based on signal transduction and cell cycle pathways.
PMID 18594202·Cell Cycle·2008
6-review
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
PMID 18332865·Oncogene·2008
8-other
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.
PMID 18423407·Adv Enzyme Regul·2008
8-other
Evidence of population-level lateralized behaviour in giant water bugs, Belostoma flumineum Say (Heteroptera: Belostomatidae): T-maze turning is left biased.
PMID 18490112·Behav Processes·2008
7-preclinical
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
PMID 17126425·Biochim Biophys Acta·2007
6-review
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
PMID 17382374·Adv Enzyme Regul·2007
7-preclinical
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
PMID 16642049·Leukemia·2006
7-preclinical
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
PMID 16854453·Adv Enzyme Regul·2006
8-other
Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines.
PMID 15917660·Cell Cycle·2005
7-preclinical
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
PMID 16185155·Expert Opin Ther Targets·2005
6-review
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
PMID 16267021·Cancer Res·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3001 FM 2181, STE 300
CORINTH, TX 76210 - Phone
- (940) 497-4900
Quick Facts
- NPI
- 1679707475
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile